CIDP Market Growth Supported by Increasing Healthcare Spending
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2026 And 2030?
The market for chronic inflammatory demyelinating polyneuropathy (CIDP) has experienced substantial growth in recent years. Projections indicate it will expand from $2.27 billion in 2025 to $2.46 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. This historical growth is attributable to heightened awareness of uncommon autoimmune neuropathies, broader accessibility of IVIG therapies, developments in electrodiagnostic testing, an increase in specialized neurological care, and enhanced identification of CIDP subtypes.
The market for chronic inflammatory demyelinating polyneuropathy (CIDP) is anticipated to demonstrate robust expansion over the next few years, with projections indicating it will reach $3.32 billion by 2030, at a compound annual growth rate (CAGR) of 7.8%. This growth during the forecast period is driven by factors such as the increasing development of targeted immunotherapies, a rising emphasis on minimizing treatment side effects, the expansion of remote patient monitoring, a growing demand for therapies providing sustained remission, and increasing investments in rare disease research. Significant trends expected in this period include the increased use of IVIG as a first-line therapy, the rising adoption of personalized treatment regimens, the growing integration of advanced diagnostic tools, the expansion of home-based treatment models, and an enhanced focus on long-term disease management.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Key Factors Are Driving The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth?
Expanding healthcare expenditure is anticipated to propel the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market in the coming years. This upward trend in healthcare spending is fueled by increased investments in medical infrastructure, a rising demand for advanced treatments, expanded insurance coverage, and government efforts to improve healthcare accessibility. Significant healthcare expenditure enhances access to advanced treatments, early diagnosis, and improved management of CIDP, leading to better patient outcomes and quality of life. For instance, in May 2024, the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure recorded a 5.6% increase in nominal terms from 2022 to 2023, which signifies a substantial acceleration compared to the 0.9% growth observed in 2022. Consequently, the increasing healthcare expenditure is driving the expansion of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
How Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Organized By Segment Classification?
The chronic inflammatory demyelinating polyneuropathy (cidp) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administrations
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Which Trends Are Guiding The Direction Of The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Businesses active within the chronic inflammatory demyelinating polyneuropathy (CIDP) market are prioritizing innovations, specifically intravenous immunoglobulin (IVIG) therapy, aiming to elevate treatment effectiveness, optimize patient recovery, and deliver more precise and potent immune regulation for CIDP care. This intravenous immunoglobulin (IVIG) therapy involves administering concentrated antibodies obtained from healthy individuals to assist in modulating the immune system and mitigating inflammation in various autoimmune disorders. An example is from January 2024, when Takeda Pharmaceutical Company Limited, a biopharmaceutical firm based in Japan, disclosed that GAMMAGARD LIQUID received FDA approval as an intravenous immunoglobulin (IVIG) treatment for adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). This clearance enables its deployment as an induction therapy, commencing with an initial dosage and then proceeding with maintenance dosages to facilitate ongoing disease management and enhance neuromuscular capabilities.
Who Are The Industry Participants Involved In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (cidp) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Hualan Biological Engineering Inc, argenx SE, Bio Products Laboratory Ltd., Kedrion S.p.A, Biotest AG, Hansa Biopharma AB, UCB SA, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, Roche Holding AG, Biogen Inc, Momenta Pharmaceuticals, Teijin Pharma Limited, Sanquin Plasma Products BV, Fresenius Kabi AG, Immunovant Sciences GmbH, Akari Therapeutics Plc, GeNeuro Pharmaceuticals, MedDay Pharmaceuticals, HanAll Pharma
Get The Full Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report:
Which Region Dominates The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market By Market Share?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2025. The regions covered in the chronic inflammatory demyelinating polyneuropathy (cidp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2026, By The Business Research Company
Optic Nerve Disorders Treatment Market Report 2026
Peripheral Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
